111 related articles for article (PubMed ID: 21770018)
1. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus.
Brandman D; Pingitore A; Lai JC; Roberts JP; Ferrell L; Bass NM; Terrault NA
Liver Transpl; 2011 Dec; 17(12):1380-6. PubMed ID: 21770018
[TBL] [Abstract][Full Text] [Related]
2. The corrected donor age for hepatitis C virus-infected liver transplant recipients.
Dirchwolf M; Dodge JL; Gralla J; Bambha KM; Nydam T; Hung KW; Rosen HR; Feng S; Terrault NA; Biggins SW
Liver Transpl; 2015 Aug; 21(8):1022-30. PubMed ID: 26074140
[TBL] [Abstract][Full Text] [Related]
3. Impact of Donor and Recipient Clinical Characteristics and Hepatic Histology on Steatosis/Fibrosis Following Liver Transplantation.
Shaked O; Demetris J; Levitsky J; Feng S; Loza BL; Punch J; Reyes J; Klintmalm G; Jackson W; DesMarais M; Sayre P; Shaked A; Reddy KR
Transplantation; 2022 Jan; 106(1):106-116. PubMed ID: 33982909
[TBL] [Abstract][Full Text] [Related]
4. The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes.
Ma X; Zhu Y; Yeo YH; Fan Z; Xu X; Rui F; Ni W; Gu Q; Tong X; Yin S; Qi X; Shi J; Wu C; Li J
Hepatol Int; 2024 Jun; 18(3):952-963. PubMed ID: 38252365
[TBL] [Abstract][Full Text] [Related]
5. Hepatic steatosis after pediatric liver transplant.
Perito ER; Vase T; Ramachandran R; Phelps A; Jen KY; Lustig RH; Feldstein VA; Rosenthal P
Liver Transpl; 2017 Jul; 23(7):957-967. PubMed ID: 28426902
[TBL] [Abstract][Full Text] [Related]
6. Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome.
Saldarriaga OA; Dye B; Pham J; Wanninger TG; Millian D; Kueht M; Freiberg B; Utay N; Stevenson HL
Sci Rep; 2021 Jul; 11(1):14506. PubMed ID: 34267267
[TBL] [Abstract][Full Text] [Related]
7. Effects of hepatitis C virus infection and its recurrence after liver transplantation on functional performance and health-related quality of life.
Feurer ID; Wright JK; Payne JL; Kain AC; Wise PE; Hale P; Chapman WC; Speroff T; Pinson CW
J Gastrointest Surg; 2002; 6(1):108-15. PubMed ID: 11986026
[TBL] [Abstract][Full Text] [Related]
8. Donor Diabetes and Steatosis Affects Recipient Survival Following Liver Transplantation Based on Etiology of Liver Cirrhosis.
Lim WH; Ng CH; Tan DJH; Xiao J; Fu CE; Ong C; Koh B; Chung C; Tan SN; Wong ZY; Mitchell K; Joseph AA; Tseng M; Syn N; Mak LY; Fung J; Huang DQ; Muthiah M; Tan EXX; Siddiqui MS
Transplantation; 2024 Feb; 108(2):473-482. PubMed ID: 37439778
[TBL] [Abstract][Full Text] [Related]
9. Effect of Donor Hepatic Steatosis on Ischemia Reperfusion Injury in Liver Transplant Recipient.
Jadhav PV; Kothakota SR; Sasidharan M; Kareem H; Nair AK
J Clin Exp Hepatol; 2020; 10(3):236-244. PubMed ID: 32405180
[TBL] [Abstract][Full Text] [Related]
10. Hepatic steatosis after liver transplantation: a systematic review and meta-analysis.
Silva AC; Nogueira P; Machado MV
Liver Transpl; 2023 Apr; 29(4):431-448. PubMed ID: 36735478
[TBL] [Abstract][Full Text] [Related]
11. Impact of Pretransplant Diabetes on Outcomes After Liver Transplantation: An Updated Meta-analysis With Systematic Review.
Tang ASP; Tan C; Lim WH; Ng CH; Tan DJH; Zeng R; Xiao J; Ong EYH; Cho E; Chung C; Lim WS; Chee D; Nah B; Tseng M; Syn N; Bonney G; Liu K; Huang DQ; Muthiah M; Siddiqui MS; Tan EXX
Transplantation; 2024 May; 108(5):1157-1165. PubMed ID: 37899382
[TBL] [Abstract][Full Text] [Related]
12. Lack of a 5.9 kDa peptide C-terminal fragment of fibrinogen α chain precedes fibrosis progression in patients with liver disease.
Marfà S; Crespo G; Reichenbach V; Forns X; Casals G; Morales-Ruiz M; Navasa M; Jiménez W
PLoS One; 2014; 9(10):e109254. PubMed ID: 25275549
[TBL] [Abstract][Full Text] [Related]
13. Fibrosis and steatosis of the liver graft: Are non-invasive tests useful? A short review.
Dumont C; Lanthier N; Dahlqvist G
Clin Res Hepatol Gastroenterol; 2023 Oct; 47(8):102194. PubMed ID: 37567467
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic steatosis is an independent risk factor for post-transplant diabetes mellitus in kidney transplant patients.
Hasbal NB; Copur S; Peltek IB; Mutlu A; Atalay HO; Kesgin YE; Karakaya AD; Siriopol D; Koçak B; Kanbay M
Clin Transplant; 2024 Jan; 38(1):e15204. PubMed ID: 38041471
[TBL] [Abstract][Full Text] [Related]
15. Visceral adiposity in cirrhosis: Association with disease severity and impact of liver transplantation.
Sharma R; Schluger A; Ahmed FS; Nobel YR; Guo X; Zhao B; Verna EC
Hepatol Commun; 2023 Jun; 7(6):. PubMed ID: 37184525
[TBL] [Abstract][Full Text] [Related]
16. Effect of donor
Kozlitina J; Cohen NM; Sturtevant D; Cohen JC; Murphey-Half C; Saltarrelli JG; Jindra P; Askar M; Hwang CS; Vagefi PA; Lacelle C; Hobbs HH; MacConmara MP
EClinicalMedicine; 2024 Jan; 67():102350. PubMed ID: 38169797
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive markers of liver steatosis and fibrosis after liver transplantation - Where do we stand?
Mikolasevic I; Stojsavljevic S; Blazic F; Mijic M; Radic-Kristo D; Juric T; Skenderevic N; Klapan M; Lukic A; Filipec Kanizaj T
World J Transplant; 2021 Mar; 11(3):37-53. PubMed ID: 33816145
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune hepatitis recurrence after liver transplantation: "Les jeux sont faits".
Chouik Y; Corpechot C; Francoz C; De Martin E; Guillaud O; Abergel A; Altieri M; Barbier L; Besch C; Chazouillères O; Conti F; Dharancy S; Durand F; Duvoux C; Gugenheim J; Hardwigsen J; Hilleret MN; Houssel-Debry P; Kamar N; Minello A; Neau-Cransac M; Pageaux GP; Radenne S; Roux O; Saliba F; Samuel D; Vanlemmens C; Woehl-Jaegle ML; Leroy V; Duclos-Vallée JC; Dumortier J
Liver Transpl; 2024 Apr; 30(4):395-411. PubMed ID: 37788303
[TBL] [Abstract][Full Text] [Related]
19. Influence of cannabis use on severity of hepatitis C disease.
Ishida JH; Peters MG; Jin C; Louie K; Tan V; Bacchetti P; Terrault NA
Clin Gastroenterol Hepatol; 2008 Jan; 6(1):69-75. PubMed ID: 18166478
[TBL] [Abstract][Full Text] [Related]
20. Liver transplantation for refractory hepatic hydrothorax is associated with a greater survival benefit compared to other complications of cirrhosis.
Osman KT; Naritsin A; Amuchi B; Qamar AA
Liver Transpl; 2024 Feb; 30(2):142-150. PubMed ID: 37450656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
